Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Lantern Pharma Inc.

LTRNNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 12:19 PM ESTFiling CIK 1763950Accession 0001172661-26-005243
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Lantern Pharma Inc.
Company CIK
0001763950
Street
1920 McKinney Avenue, 7th Floor
City
Dallas
State / country code
TX
Postal code
75201

Statement details

Security class
Common Stock, par value of $0.0001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Armistice Capital, LLC
Citizenship / organization
DE
Reporting person type
IA · OO
Aggregate amount owned
1,542,681.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
1,542,681.00
Sole dispositive power
0.00
Shared dispositive power
1,542,681.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Steven Boyd
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
1,542,681.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
1,542,681.00
Sole dispositive power
0.00
Shared dispositive power
1,542,681.00
Aggregate excludes certain shares
N

Item 1

Issuer

Lantern Pharma Inc.

Principal executive office address

1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201

Item 2

Citizenship

Armistice Capital, LLC - Delaware; Steven Boyd - United States of America

Filing person

Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"

Principal business or residence address

Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America

Item 3

Not applicable indication

N

Type of filing person

IA · HC

Item 4

Percent of class

9.99%

Amount beneficially owned

1,542,681

Sole voting power

0

Shared voting power

1,542,681

Sole dispositive power

0

Shared dispositive power

1,542,681 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Signature 1

Reporting person
Armistice Capital, LLC
Signed
/s/ Steven Boyd
Title
Steven Boyd - Managing Member
Date
11/16/2026

Signature 2

Reporting person
Steven Boyd
Signed
/s/ Steven Boyd
Title
Steven Boyd
Date
11/16/2026

Company context

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical t

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 18, 2026
  2. 10-Q filingNov 17, 2026
  3. NT 10-Q filingNov 17, 2026
  4. ARS filingOct 21, 2026
  5. DEF 14A filingOct 19, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.